Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
56.21
+0.98 (+1.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation
January 10, 2024
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in an effort to rejuvenate the company's image, attract a younger...
Via
Benzinga
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
January 05, 2024
Shares soared and then tumbled Friday after the company offered $275 million in public shares.
Via
Investor's Business Daily
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
January 04, 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year
Via
Talk Markets
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
January 02, 2024
Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD
Via
Benzinga
Why NASDAQ:SNY is a Top Pick for Dividend Investors.
January 02, 2024
Analyzing SANOFI-ADR (NASDAQ:SNY)'s Dividend Potential.
Via
Chartmill
Looking Into Sanofi's Recent Short Interest
December 21, 2023
Via
Benzinga
Why NASDAQ:SNY provides a good dividend, while having solid fundamentals.
December 12, 2023
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals.
Via
Chartmill
How Is The Market Feeling About Sanofi?
November 30, 2023
Via
Benzinga
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
December 29, 2023
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...
Via
Benzinga
NASDAQ:SNY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
December 28, 2023
SANOFI-ADR (NASDAQ:SNY): good value for what you're paying.
Via
Chartmill
Why First Wave BioPharma Shares Are Skyrocketing Today
December 27, 2023
First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are skyrocketing Wednesday after the company entered a non-binding term sheet to sell its Niclosamide program for the treatment of
Via
Benzinga
Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today?
December 21, 2023
MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson (NYSE: JNJ) compan
Via
Benzinga
European Drugmaker Sanofi Ends Tusamitamab Ravtansine Lung Cancer Program After Disappointing Data
December 21, 2023
Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development pr
Via
Benzinga
First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline
December 18, 2023
First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for...
Via
Benzinga
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
December 17, 2023
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.
Via
InvestorPlace
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
December 17, 2023
You can pick these players up for a great price right now.
Via
The Motley Fool
French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment
December 15, 2023
Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium
Via
Benzinga
3 Stocks to Buy Before 2024 That Can Set You Up For Life
December 14, 2023
These stocks are still relatively cheap, but don't expect them to stay that way for long.
Via
The Motley Fool
French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle
December 12, 2023
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission (FTC)
Via
Benzinga
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company
December 07, 2023
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S.
Via
Benzinga
Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities
December 07, 2023
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus
Via
Benzinga
IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies
December 06, 2023
IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM...
Via
Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
December 06, 2023
Merck KGaA (OTC: MKGAF) (OTC:
Via
Benzinga
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.
December 06, 2023
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift
December 05, 2023
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.
Via
Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
December 01, 2023
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...
Via
Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 30, 2023
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
Via
The Motley Fool
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
November 27, 2023
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation.
Via
Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
November 27, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...
Via
Benzinga
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
November 22, 2023
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.